ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

The majority of lipid-lowering drug prescriptions dispensed in the Canadian province of British Columbia are for population groups for which there is no research evidence to support the use of such drugs. So says Dr Isabelle Savoie from the British Columbia Office of Health Technology Assessment, Vancouver, Canada. She made this comment at the 14th Annual Meeting of the International Society of Technology Assessment in Health Care (ISTAHC) [Ottawa, Canada; June 1998] during a presentation of pharmacoeconomic studies of lipid-lowering drug therapy. The preliminary results of Dr Savoie's study1and those of other presenters at the session are discussed below.

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

摘要:

Supercomputers can help design antineoplastic agents in a fraction of the time it would take mere mortals using conventional computers. Although speedy discovery does not ensure a new drug will be effective or safe, it does allow researchers to vet hundreds of potential candidates very quickly. The drug development process can then be slowed down as the compound undergoes a series of conventional molecular and laboratory tests. Two drugs discovered through this process, and now in phase I studies, were described at the 10th NCI-EORTC*Symposium on New Drugs in Cancer Therapy [Amsterdam, The Netherlands; June 1998].

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1998

数据来源: ADIS